Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-101 Gene Therapy for Beta-Thalassemia Major
NCT04211480Phase 2Completed
- Sponsor
- BRL Medicine Inc.
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Gene Silencing, CRISPR-Cas9, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BRL-101 in beta thalassemia, sponsored by BRL Medicine Inc.. Started Oct 2020; status: completed.
02
Drugs
BRL-101
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04211480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211480.